Mostrar el registro sencillo del ítem
dc.contributor.author
Wagner, Gernot
dc.contributor.author
Nussbaumer Streit, Barbara
dc.contributor.author
Greimel, Judith
dc.contributor.author
Ciapponi, Agustín
dc.contributor.author
Gartlehner, Gerald
dc.date.available
2018-08-29T20:49:32Z
dc.date.issued
2017-08
dc.identifier.citation
Wagner, Gernot; Nussbaumer Streit, Barbara; Greimel, Judith; Ciapponi, Agustín; Gartlehner, Gerald; Trading certainty for speed - How much uncertainty are decisionmakers and guideline developers willing to accept when using rapid reviews: An international survey; BioMed Central; Bmc Medical Research Methodology; 17; 1; 8-2017; 1-8
dc.identifier.issn
1471-2288
dc.identifier.uri
http://hdl.handle.net/11336/57602
dc.description.abstract
Background: Decisionmakers and guideline developers demand rapid syntheses of the evidence when time sensitive evidence-informed decisions are required. A potential trade-off of such rapid reviews is that their results can have less reliability than results of systematic reviews that can lead to an increased risk of making incorrect decisions or recommendations. We sought to determine how much incremental uncertainty about the correctness of an answer guideline developers and health policy decisionmakers are willing to accept in exchange for a rapid evidence-synthesis. Methods: Employing a purposive sample, we conducted an international web-based, anonymous survey of decisionmakers and guideline developers. Based on a clinical treatment, a public health, and a clinical prevention scenario, participants indicated the maximum risk of getting an incorrect answer from a rapid review that they would be willing to accept. We carefully reviewed data and performed descriptive statistical analyses. Results: In total, 325 (58.5%) of 556 participants completed our survey and were eligible for analysis. The median acceptable incremental risk for getting an incorrect answer from a rapid review across all three scenarios was 10.0% (interquartile range [IQR] 5.0-15.0). Acceptable risks were similar for the clinical treatment (n = 313, median 10.0% [IQR 5.0-15.0]) and the public health scenarios (n = 320, median 10.0% [IQR 5.0-15.0]) and lower for the clinical prevention scenario (n = 312, median 6.5% [IQR 5.0-10.5]). Conclusions: Findings suggest that decisionmakers are willing to accept some trade-off in validity in exchange for a rapid review. Nevertheless, they expect the validity of rapid reviews to come close to that of systematic reviews.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
BioMed Central
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Decision-Making
dc.subject
Decisionmaker
dc.subject
Guideline Developer
dc.subject
Rapid Review
dc.subject
Systematic Review
dc.subject
Uncertainty
dc.subject.classification
Otras Ciencias de la Salud
dc.subject.classification
Ciencias de la Salud
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Trading certainty for speed - How much uncertainty are decisionmakers and guideline developers willing to accept when using rapid reviews: An international survey
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2018-08-27T17:59:39Z
dc.journal.volume
17
dc.journal.number
1
dc.journal.pagination
1-8
dc.journal.pais
Reino Unido
dc.journal.ciudad
Londres
dc.description.fil
Fil: Wagner, Gernot. Danube University Krems; Alemania
dc.description.fil
Fil: Nussbaumer Streit, Barbara. Danube University Krems; Alemania
dc.description.fil
Fil: Greimel, Judith. Universidad de Hohenheim; Alemania
dc.description.fil
Fil: Ciapponi, Agustín. Instituto de Efectividad Clínica y Sanitaria; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Gartlehner, Gerald. Danube University Krems; Alemania
dc.journal.title
Bmc Medical Research Methodology
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1186/s12874-017-0406-5
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-017-0406-5
Archivos asociados